Limited Competition Cohort Studies of HIV/AIDS and Substance Abuse (U01)

The summary for the Limited Competition Cohort Studies of HIV/AIDS and Substance Abuse (U01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Limited Competition Cohort Studies of HIV/AIDS and Substance Abuse (U01): The National Institute on Drug Abuse supported a number of HIV/AIDS cohorts among substance abusing populations. These cohorts address emerging and high priority research on HIV/AIDS. These longitudinal cohorts serve as a strong resource platform for current and future collaborative efforts with other investigators to address emerging questions related to HIV infection, prevention, and treatment in the context of substance abuse, as well as to foster the creativity and efficiency of investigator-initiated research. Accomplishments by the NIDA-funded cohorts have been highly significant. Four of these cohorts (see below) will be terminated within a year if continued support is not provided. Therefore, the purpose of this Limited Competition Funding Opportunity Announcement (FOA) is to support the maintenance and expansion of these NIDA-funded cohorts to continue to address new emerging and/or high priority research on multidisciplinary aspects of HIV/AIDS and substance abuse. This FOA will provide continued support for recruiting and retaining participants in the cohort(s) to provide insight into the changing demographics of the HIV epidemic among this high risk population in the United States (U.S.). This FOA will also continue to provide a strong resource platform for current and future collaborative efforts with other investigators to address new and emerging questions related to HIV infection, prevention, and/or treatment in the context of substance abuse, as well as to foster the creativity and efficiency of investigatorinitiated research goals.
Federal Grant Title: Limited Competition Cohort Studies of HIV/AIDS and Substance Abuse (U01)
Federal Agency Name: National Institutes of Health (HHS-NIH11)
Grant Categories: Education Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-DA-18-011
Type of Funding: Cooperative Agreement
CFDA Numbers: 93.279
CFDA Descriptions: Information not provided
Current Application Deadline: September 29th, 2017
Original Application Deadline: September 29th, 2017
Posted Date: June 14th, 2017
Creation Date: June 14th, 2017
Archive Date: November 4th, 2017
Total Program Funding: $6,000,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards: 4
Cost Sharing or Matching: No
Last Updated: June 14th, 2017
Applicants Eligible for this Grant
Private institutions of higher education
Additional Information on Eligibility
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. See FOA for full eligibility details.
Link to Full Grant Announcement
http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-18-011.html
Grant Announcement Contact
NIH OER Webmaster
[email protected]

If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants
Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...
Education Activities for Responsible Analyses of Complex, Large-Scale Data (R25- Clinical ...
Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Tr...
Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Tr...
Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial option...
NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards
Drug Abuse Aspects of Hiv/Aids and Other Infections
Epidemiology of Drug Abuse
More Grants from the National Institutes of Health
SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies...
Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Al...
Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional)
Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial No...
Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimenta...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2024 FederalGrants.com